iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer

iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer

Pancreatic cancer is one of the leading causes of cancer-related death, with 5-year survival of 8.5%. The lack of significant progress in improving therapy reflects our inability to overcome the desmoplastic stromal barrier in pancreatic ductal adenocarcinoma (PDAC) as well as a paucity of new appro...

Full description

Bibliographic Details
Main Authors: Lo, Justin H. (Author), Hao, Liangliang (Author), Muzumdar, Mandar (Author), Raghavan, Srivatsan (Author), Kwon, Ester (Author), Pulver, Emilia M (Author), Hsu, Felicia (Author), Aguirre, Andrew J. (Author), Wolpin, Brian M. (Author), Fuchs, Charles S. (Author), Hahn, William C. (Author), Jacks, Tyler E (Author), Bhatia, Sangeeta N (Author)
Other Authors: Massachusetts Institute of Technology. Institute for Medical Engineering & Science (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor)
Format: Article
Language:English
Published: American Association for Cancer Research (AACR), 2020-12-04T20:40:05Z.
Subjects:
Article
Online Access:Get fulltext

Similar Items

Similar Items